1: Giving docetaxel at the same time as ADT to men with metastatic prostate cancer extends overall survival by an average of 15 months – results from STAMPEDE

The much anticipated official results of the docetaxel arm of the STAMPEDE trial have been published in the Lancet. The trial reported an almost unprecedented survival benefit for men newly diagnosed with metastatic prostate cancer, when they were given docetaxel chemotherapy as a first line treatment alongside ADT. On average, men receiving ADT + docetaxel lived 15 months longer than those receiving ADT alone, the current standard of care.

Find out more about how we’ve been working with NHS England to ensure this research leads to a change in clinical practice here.

2: Prostate cancer patients are more likely to survive if they undergo surgery rather than radiation

systematic review and meta-analysis of 19 studies and 118,830 patients has found that radiotherapy is associated with an increased risk of overall and prostate cancer-specific mortality compared with surgery, in men with localised prostate cancer.

Both treatment approaches should be discussed with patients prior to the start of therapy. The important thing about this research is that it gives clinicians and patients additional information to consider when making the decision about how to treat localised prostate cancer.

The randomised controlled trial ProtecT, due to report next year, will provide definitive evidence for the best treatment for men with localised prostate cancer.

Health professional news archive
comments powered by Disqus